ArticleDigestive diseases and sciences2025
Association Between High FIB-4 Score and the Risk of Malignancy Development and Mortality: A Retrospective Longitudinal Case-Control Study.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients.Journal of personalized medicine · 2026Article
- Joint association of inflammatory markers and sedentary time with mortality in metabolic dysfunction-associated steatotic liver disease population and the mediating role of inflammation.European journal of medical research · 2025Article
- Article
- Integrative Assessment of TyG Index, FIB-4, and eGFR as Composite Predictors of Metabolic Risk Clusters in Adults.Metabolites · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Fibrosis 4 (FIB-4) score, a widely used non-invasive marker for liver fibrosis in chronic liver disease, has recently been linked to systemic inflammation, cardiovascular risk, and mortality. However, its potential role in predicting malignancy risk and long-term outcomes in patients without known chronic liver disease remains unclear.
methodsWe conducted a retrospective case-control study analyzing 43,080 patients from Leumit Health Services in Israel between 2002 and 2023. Of them, 21,540 had high FIB-4 levels > 2.67 and the 21,540 controls had low FIB-4 < 1.5. Patients from both groups were matched 1:1 according to gender, socioeconomic status, and birth year. The study surveyed both the prevalence of malignancies in both groups at baseline and during a 10-year follow-up period.
resultsAt baseline, the high FIB-4 group showed strong associations with existing malignancies, particularly pancreatic cancer (odds ratio [OR] = 27.53), hepatocellular carcinoma (OR = 14), and metastatic stage of any cancer (OR = 17.47). During the 10-year follow-up, while odds ratios decreased, significant risk for developing new malignancies persisted, including hepatocellular carcinoma (OR = 13.63); pancreatic (OR = 5.16), breast (OR = 2.88), and colon cancers (OR = 2.75); and metastatic stage of any cancer (OR = 6.41). The cumulative incidence of solid tumors increased from 15.84% to 22.30% in the high FIB-4 group compared with 4.85% to 9.65% in controls (at baseline and after 10 years, respectively). Additionally, the mortality rate was more than doubled in the high FIB-4 group (20.15% versus 9.72%; OR = 2.34).
conclusionsAn elevated FIB-4 score appears to be associated with both existing malignancies and an increased risk of future cancer development. These associations remain significant independently of traditional cardiovascular risk factors and body mass index (BMI). Our findings suggest that the FIB-4 score may have potential utility as a marker for cancer risk stratification and warrant further investigation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.